Jayne DRW, Merkel PA, Schall TJ, et al. - This randomized, controlled trial was conducted to test avacopan, the C5a receptor inhibitor, as a treatment choice for antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis. Herein, patients with ANCA-associated vasculitis were allocated in a 1:1 ratio to receive oral avacopan at a dose of 30 mg twice daily or oral prednisone on a tapering schedule. Either cyclophosphamide (followed by azathioprine) or rituximab was administered to all patients. Findings demonstrated that treatment with avacopan for ANCA-associated vasculitis was noninferior but not superior to prednisone taper in terms of remission at week 26 and was superior to prednisone taper in terms of sustained remission at week 52. In the trial, the safety as well as the clinical impacts of avacopan beyond 52 weeks were not addressed.